OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
RICHLAND, Wash., April 26, 2018 -- IsoRay, Inc. (the “Company”) (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced that it will host a teleconference to discuss third quarter fiscal 2018 financial results on Thursday, May 3, 2018, at 4:30 p.m. Eastern Time. The Company will issue a press release announcing its financial results for the third quarter of fiscal 2018 ended March 31, 2018, immediately after the close of the market on May 3, 2018.
Interested parties are asked to dial-in approximately 10 minutes before the call begins at the following numbers:
U.S. Participants: (877) 270-2148
International Participants: + 1-412-902-6510
Participant Passcode: 10119919
The earnings release and a replay of the call will be available through the Investor Relations section of the Company’s website: https://isoray.com/about/investors/presentations/. A replay of the call will be available for one week beginning at approximately 10:00 p.m. Eastern Time on May 3, 2018. The playback can be accessed by dialing (877) 344-7529 (U.S.) and +1-412-317-0088 (International). The passcode is 10119919.
About IsoRay, Inc.
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com. Join us on Facebook/IsoRay. Follow us on Twitter @IsoRay.
Contacts: IsoRay, Inc. [email protected] (509) 375-1202 Investors: Stephanie Prince, Managing Director PCG Advisory Group [email protected] (646) 762-4518
